ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Liminal BioSciences Resubmits BLA for Ryplazim for Congenital Plasminogen Deficiency
September 17, 2020Liminal BioSciences announced the Company, through its U.S. subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the Biologics License Application (BLA) for Ryplazim® (plasminogen) (Ryplazim®) with the U.S. Food and Drug Administration...
Pharma Sources Insight January 2025
